Prudence Francis, MD, and Hope Rugo, MD, on the Phase III SOFT Trial

2014 San Antonio Breast Cancer Symposium
Tweet this page

Prudence Francis, MD, of Peter MacCallum Cancer Centre, and Hope Rugo, MD, of the University of California, San Francisco, discuss data from abstract S3-08, "Randomized comparison of adjuvant tamoxifen plus ovarian function suppression vs tamoxifen in premenopausal women with hormone receptor–positive early breast cancer: Analysis of the SOFT trial."

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.